Aldeyra Therapeutics (ALDX) Change in Acquisitions & Divestments (2016 - 2025)

Aldeyra Therapeutics (ALDX) has 9 years of Change in Acquisitions & Divestments data on file, last reported at $16.0 million in Q4 2025.

• Quarterly Change in Acquisitions & Divestments fell 20.0% year-over-year to $16.0 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $65.0 million (down 13.33% YoY) and the FY2025 annual result came in at $88.0 million, up 69.23% from the prior year.
• Change in Acquisitions & Divestments slipped to $16.0 million in Q4 2025, from $25.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $30.0 million in Q1 2023 to a low of $12.0 million in Q2 2022.
• A 4-year average of $21.2 million and a median of $23.0 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• The widest YoY moves for Change in Acquisitions & Divestments: up 100.0% in 2025, down 20.0% in 2025.
• Tracing ALDX's Change in Acquisitions & Divestments over 4 years: stood at $27.0 million in 2022, then rose by 11.11% to $30.0 million in 2023, then plunged by 33.33% to $20.0 million in 2024, then slipped by 20.0% to $16.0 million in 2025.
• The last three Change in Acquisitions & Divestments figures came in at $16.0 million (Q4 2025), $25.0 million (Q3 2025), and $24.0 million (Q2 2025), per Business Quant data.